XML 37 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
License and Collaboration Agreements (Tables)
 6 Months Ended
Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

 

          Three months ended
June 30,		      Six months ended
June 30,		  

Partner

   

Drug or Drug Candidate

    2014      2013      2014      2013  

Roche

    PEGASYS® and MIRCERA®    $ 3,219       $ 2,625       $ 6,415       $ 5,250   

Bayer Healthcare LLC

    BAY41-6551 (Amikacin Inhale)      2,393         13,111         3,146         13,825   

Amgen, Inc.

    Neulasta®      1,250         1,250         2,500         2,535   

Baxter Healthcare

    BAX 855 (Hemophilia)      669         597         1,006         1,297   

Other

         10,254         1,776         12,799         2,928   
     

 

 

     

 

 

     

 

 

     

 

 

  

License, collaboration, and other revenue

       $ 17,785       $ 19,359       $ 25,866       $ 25,835